toll free: 1800 3070 6727 Email: firstname.lastname@example.org
All Ovarian cancer patients
Approved by US FDA
BRCA positive patients can benefit with PARP inhibitors
Testing BRCA gene mutation on Tumor helps identify 50% more patients eligible for treatment with PARP inhibitors
Sample Requirement: FFPE Blocks or Blood
Illumina Next Generation Sequencing
CAP & CLIA certified laboratory
Reporting time: 3 weeks
Download sample report
BRACAnalysis CDx is an US-FDA approved companion diagnostic test for Ovarian cancer patients looking to get treated with a PARP inhibitor. It covers BRCA1 and BRCA2 genes.Test is conducted on FFPE tumor blocks which is much more accurate than testing on blood.
My mother had ovarian cancer. After taking cisplatin we were looking for a therapy to maintain her response. We underwent BRACAnalysisCDX which was positive in her case and we started giving her Olaparib.
Better understand a patients’ risk for specific health conditions
Prescribe more suitable medications at optimal dosages for patients, as needed.
Suggest early lifestyle and diet interventions to help control or prevent certain health conditions.
Best treatment recommendation
Provides information on pathway analysis
Includes Positive Bioscience expert comments and complementary consulation with your docto
65% increase in median overall survival
Multiple technology platform to provide most comprehensive recommendations
31% more accurate in identifying cancer driver mutations
Better treatment recommendation
Complementary consultation with your doctor
533, Kalbadevi Road,
Mumbai – 400002